ExomeDx™ Prenatal (Trio)
Use
ExomeDx™ Prenatal Trio is indicated when fetal anomalies are detected via ultrasound and chromosomal microarray (CMA) and karyotype are non‑diagnostic. This comprehensive sequencing includes parental samples (trio) to interpret inheritance and improve diagnostic yield.
Special Instructions
Parental (maternal and paternal) specimens must be submitted along with the proband sample. GeneDx provides complimentary prenatal kits in the U.S. and Canada. Maternal cell contamination analysis is performed for prenatal specimens; maternal blood or buccal sample is required for comparison.
Limitations
Turnaround times are estimates and begin only after billing and clinical reviews—delays outside the laboratory’s control may extend TAT. Diagnostic yield may vary depending on phenotype; CMA and karyotype must be non‑diagnostic. Interpretation of prenatal variants may be constrained; VUS may require postnatal reanalysis.
Methodology
NGS (Targeted)
Biomarkers
Result Turnaround Time
7-14 days
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
Not provided
Minimum Volume
Not provided